AML 17: A Programme of Treatment Development in Younger Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome
Latest Information Update: 22 Jan 2024
At a glance
- Drugs Arsenic trioxide (Primary) ; Clofarabine (Primary) ; Gemtuzumab ozogamicin (Primary) ; Laromustine (Primary) ; Cytarabine; Daunorubicin; Etoposide; Everolimus; Fludarabine; Idarubicin; Lestaurtinib; Pacritinib; Temsirolimus; Tretinoin
- Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Myelodysplastic syndromes
- Focus Registrational; Therapeutic Use
- Acronyms AML-17; NCRI AML17
- 12 Dec 2023 Results assessing comprehensive genotyping and molecular MRD assessment in two consecutive prospective randomised studies (NCRI AML17 (2009-2014) and AML19 (2015-2020)) presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 10 Dec 2023 According to an American Society of Hematology media release, data from this study are being presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition highlight, by Jad Othman.
- 10 Dec 2023 Results presented in an American Society of Hematology media release.